4.6 Article

The Effect of 6 Versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)

Related references

Note: Only part of the references are listed.
Article Endocrinology & Metabolism

Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research

Elizabeth Shane et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2010)

Article Endocrinology & Metabolism

Fracture risk remains reduced one year after discontinuation of risedronate

N. B. Watts et al.

OSTEOPOROSIS INTERNATIONAL (2008)

Article Medicine, General & Internal

Zoledronic acid and clinical fractures and mortality after hip fracture

Kenneth W. Lyles et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Article Medicine, General & Internal

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

Dennis M. Black et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Letter Medicine, General & Internal

Alendronate and atrial fibrillation

Steven R. Cummings et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Article Medicine, General & Internal

Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial

Dennis M. Black et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)

Article Medicine, General & Internal

Ten years' experience with alendronate for osteoporosis in postmenopausal women

HG Bone et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

Article Endocrinology & Metabolism

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis

CH Chesnut et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2004)

Article Medicine, General & Internal

Effect of risedronate on the risk of hip fracture in elderly women

MR McClung et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)